Inhalation and particle engineering specialist Hovione and Swiss chemical development company Solvias have announced an agreement to collaborate on development and manufacturing of co-crystallized drugs. According to Hovione, “This strengthens Hovione’s expertise and experience in overcoming drug delivery challenges and also the supply of GMP materials from phase I to commercial scale, with Solvias’ excellence in solid state chemistry.”
Hovione VP of Particle Design Colin Minchom commented, “We are delighted to announce this collaboration with Solvias increasing the breadth of drug delivery solutions through our Particle Design offering. Solvias has a tremendous reputation for science, quality and expertise in crystal design for improved drug performance. This agreement reinforces our strategy of combining strengths with innovative companies to allow our customers a seamless and integrated approach to their drug delivery challenges.”
Read the Hovione press release.
